Abstract | PURPOSE: METHODS: RESULTS: Although all cancer cells expressed the angiogenic factors, SCC7 cells had much higher angiogenic potential and grew rapidly after implantation into mice. When orally administered, LHD delayed tumor graft growth regardless of cancer types. Particularly, LHD powerfully diminished the SCC7-derived tumor growth. Also, the expression of angiogenic factors in all kinds of tumor tissues was decreased, thereby attenuating the neovascularization in tumor tissue. CONCLUSION: Our study shows that LHD has potent anticancer and antiangiogenic effect on at least three kinds of tumor cells. LHD can be specifically used for preventing neovascularization in tumor tissue because it has therapeutical potential as an antiangiogenic drug and can be orally absorbed.
|
Authors | Dong Yun Lee, Sung Won Lee, Sang Kyoon Kim, Myungjin Lee, Hyo Won Chang, Hyun Tae Moon, Youngro Byun, Sang Yoon Kim |
Journal | Pharmaceutical research
(Pharm Res)
Vol. 26
Issue 12
Pg. 2667-76
(Dec 2009)
ISSN: 1573-904X [Electronic] United States |
PMID | 19830530
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Heparin, Low-Molecular-Weight
- LMWH-DOCA conjugate
- Deoxycholic Acid
|
Topics |
- Absorption
- Administration, Oral
- Angiogenesis Inhibitors
(pharmacology, therapeutic use)
- Animals
- Carcinoma, Squamous Cell
(drug therapy, pathology)
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Deoxycholic Acid
(analogs & derivatives, pharmacology, therapeutic use)
- Disease Models, Animal
- Heparin, Low-Molecular-Weight
(analogs & derivatives, pharmacology, therapeutic use)
- Humans
- Immunohistochemistry
- Lung Neoplasms
(drug therapy, pathology)
- Melanoma
(drug therapy, pathology)
- Mice
- Mice, Inbred C57BL
- Molecular Structure
|